AtriCure stock gains as analysts highlight upside and valuation risks

Published on 09/18/2026 at 20:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AtriCure stock closed at USD 59.12 on September 17, 2026, near its 52-week high after a 3.4% daily gain. Recent analyst targets up to USD 65.00 and an overvaluation signal frame a mixed risk-reward profile for investors.

ATRC, US04963C1099, Illustration mit AI erstellt.

AtriCure Inc. stock (ISIN US04963C1099) closed at USD 59.12 on the Nasdaq on September 17, 2026, after a 3.4% gain that pushed the shares close to their 52-week high of USD 59.59, highlighting strong recent momentum for the medical device maker.

Analysts see upside but warn on valuation

According to The Globe and Mail on September 18, 2026, Stifel Nicolaus analyst Rick Wise maintains a Buy rating on AtriCure with a price target of USD 65.00, compared with a prior closing level of USD 57.14 referenced in the note.

The same overview cites a Strong Buy consensus on AtriCure, with an average analyst price target of USD 55.00, implying about 1.2% downside from current levels around USD 59.12 and underlining that some houses already see the stock trading ahead of their targets.The Globe and Mail The report also notes that Needham reiterated its Buy rating on AtriCure with a USD 64.00 price target in a note issued on September 2, 2026, adding a second bullish benchmark slightly below the Stifel level.The Globe and Mail

GF Score and valuation metrics put price in perspective

As GuruFocus reported on September 17, 2026, AtriCure shares rose 3.4% on that trading day to close at USD 59.12, within a 52-week range between USD 25.36 and USD 59.59, which means the stock now trades almost at the top of its one-year band.

The same analysis assigns AtriCure a GF Score of 75 out of 100, categorized as above average overall but with a low valuation rank, and calculates a GF Value estimate of USD 39.85, placing the closing price of USD 59.12 about 48.4% above this intrinsic value yardstick and labeling the shares as significantly overvalued.GuruFocus For investors, this creates a tension between near-term price strength and longer-term valuation risk, particularly as the GF Valuation label explicitly classifies AtriCure stock as 'Significantly Overvalued' and points to a limited margin of safety at current levels.GuruFocus

Market backdrop and fundamental context

The GuruFocus piece notes that AtriCure's recent performance has been driven by strong price appreciation, with the share price more than doubling from the 52-week low of USD 25.36 to the recent close of USD 59.12, a gain of roughly 133% over the period, underscoring why valuation metrics are now under closer scrutiny.GuruFocus In parallel, Macrotrends lists AtriCure with a market capitalization of about USD 1.772 billion in its sector comparison overview, positioning the company as a mid-cap player within the broader medical technology landscape.Macrotrends

While the latest detailed quarterly figures are not highlighted in the week-filtered sources, investor attention currently appears focused on the balance between growth expectations embedded in analyst targets of USD 64.00 to USD 65.00 and the valuation warnings signaled by a GF Value estimate nearly USD 19.27 below the market price, a spread that indicates investors are paying a sizable premium relative to that particular intrinsic value model.The Globe and Mail For risk-aware investors, the key question is how sustainable the recent share-price surge will prove if future earnings or procedure adoption trends deviate from the optimistic scenarios underlying the higher price targets and GF Score components.

Stock near yearly high after recent surge

Per the GuruFocus snapshot, AtriCure stock's closing price of USD 59.12 on September 17, 2026, sits just USD 0.47 below the 52-week high of USD 59.59, leaving only about 0.8% headroom to that recent peak and signaling that the market has already priced in a substantial amount of good news in the short term.GuruFocus With analyst targets such as USD 65.00 from Stifel and USD 64.00 from Needham still signaling potential upside of around 9.9% to 11.0% from the latest close, the combination of a stretched valuation label and remaining room to these targets makes AtriCure stock a closely watched name for investors balancing growth ambitions against valuation discipline.The Globe and Mail